GSK plcLSE: GSK

Q3 2026 US dollar translation

Oct 28, 2026 at 3:24 AM EDT · Issued by GSK plc

Summary by 6ix AI

GSK published a US dollar convenience translation of its unaudited results for the nine months ended September 30, 2026. Turnover was £24,925 million (US$33,400 million) and profit attributable to shareholders was £3,715 million (US$4,978 million).

Key details

Operating profit for the nine months ended September 30, 2026 was £4,901 million (US$6,567 million), and profit before taxation was £4,433 million (US$5,940 million).
Earnings per share were 92.5p (124.0 US cents), and diluted earnings per share were 91.1p (122.0 US cents).
By business for the nine months: Specialty Medicines turnover £10,885 million (US$14,587 million), Vaccines £7,016 million (US$9,401 million) and General Medicines £7,024 million (US$9,412 million). US turnover was £12,976 million (US$17,389 million).
At September 30, 2026, total assets were £71,699 million (US$95,361 million), net assets £18,362 million (US$24,422 million) and cash and cash equivalents £2,934 million (US$3,902 million).
The dollar amounts are a translation of the sterling figures: income statement and sales figures use average exchange rates for the period, and balance sheet figures use the closing rate at September 30, 2026.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/gsk-q3-2026-us-dollar-translation

GSK's next earnings callGSK (LSE:GSK) Q3 2026 Earnings Call · Oct 28, 2026 at 8:00 AM EDTRegister

‌This US dollar translation of the unaudited Results Announcement for 9 months 2026 should be read in conjunction with the Annual Report 2025, which was prepared in accordance with United Kingdom adopted International Financial Reporting Standards and has been prepared applying consistent accounting policies to those applied by the Group in the Annual Report 2025.

US Dollar amounts shown in the tables below are a convenience translation of the sterling amounts. These tables are unaudited.

Income statement

	9 months 2026 £m	9 months 2026 $m
TURNOVER	24,925	33,400
Cost of sales	(6,531)	(8,752)
Gross profit	18,394	24,648
Selling, general and administration	(6,704)	(8,983)
Research and development	(7,141)	(9,569)
Royalty income	657	880
Other operating income/(expense)	(305)	(409)
OPERATING PROFIT	4,901	6,567
Finance income	109	146
Finance expense	(568)	(761)
Share of after tax profit/(loss) of associates and joint ventures	(9)	(12)
PROFIT BEFORE TAXATION	4,433	5,940
Taxation	(338)	(453)
PROFIT AFTER TAXATION	4,095	5,487
Profit attributable to non-controlling interests	380	509
Profit attributable to shareholders	3,715	4,978
Profit attributable to shareholders	4,095	5,487
EARNINGS PER SHARE	92.5p	124.0c
Diluted earnings per share	91.1p	122.0c

In the income statement above US dollar results for 9 months 2026 are calculated using average rates for the period

‌In the detailed sales tables below US dollar results for nine months ended 30 September 2026 are calculated using average rates for the period

‌Sales tables

Specialty Medicines turnover - nine months ended 30 September 2026

	Total	US	Europe International	Total	US	Europe International
	£m	£m	£m £m	$m	$m	$m $m
HIV	6,018	4,203	1,205 610	8,066	5,633	1,615 818
Dolutegravir products	4,181	2,622	1,011 548	5,604	3,514	1,355 735
Dovato	2,169	1,218	673 278	2,907	1,632	902 373
Juluca	487	393	86 8	653	527	115 11
Tivicay	948	581	165 202	1,271	779	221 271
Triumeq	577	430	87 60	773	576	117 80
Long Acting Injectables	1,702	1,469	180 53	2,281	1,969	241 71
Apretude	403	387	4 12	540	519	5 16
Cabenuva	1,299	1,082	176 41	1,741	1,450	236 55
Other	135	112	14 9	181	150	19 12
Respiratory, Immunology & Inflammation	3,164	2,064	519 581	4,240	2,766	695 779
Benlysta	1,402	1,147	112 143	1,879	1,537	150 192
Exdensur	56	33	4 19	74	44	5 25
Nucala	1,676	884	410 382	2,246	1,185	549 512
Other	30	-	(7) 37	41	-	(9) 50
Oncology	1,703	1,087	428 188	2,281	1,457	573 251
Blenrep	109	55	35 19	146	74	47 25
Jemperli	753	543	145 65	1,009	728	194 87
Jideytro	3	3	- -	4	4	- -
Ojjaara/Omjjara	526	350	113 63	704	469	151 84
Zejula	319	136	141 42	427	182	189 56
Other	(7)	-	(6) (1)	(9)	-	(8) (1)
Specialty Medicines	10,885	7,354	2,152 1,379	14,587	9,856	2,883 1,848

‌Vaccines turnover - nine months ended 30 September 2026

	Total	US	Europe International	Total	US	Europe International
	£m	£m	£m £m	$m	$m	$m $m
Shingles	2,694	924	1,184 586	3,610	1,238	1,587 785
Shingrix	2,694	924	1,184 586	3,610	1,238	1,587 785
Meningitis	1,396	619	473 304	1,870	829	634 407
Bexsero	972	315	466 191	1,303	422	625 256
Menveo	352	257	6 89	471	344	8 119
Penmenvy	47	47	- -	63	63	- -
Other	25	-	1 24	33	-	1 32
RSV	452	138	176 138	606	185	236 185
Arexvy	452	138	176 138	606	185	236 185
Influenza	198	129	18 51	265	173	24 68
Fluarix, FluLaval	198	129	18 51	265	173	24 68
Other Paediatric & Adult Vaccines	2,276	1,050	559 667	3,050	1,407	749 894
Boostrix	551	359	112 80	739	481	150 108
Hepatitis	496	246	152 98	665	330	204 131
Infanrix, Pediarix	384	228	83 73	515	306	111 98
Priorix, Priorix Tetra, Varilrix	246	54	103 89	329	72	138 119
Rotarix	419	151	88 180	561	202	118 241
Other	180	12	21 147	241	16	28 197
Vaccines	7,016	2,860	2,410 1,746	9,401	3,832	3,230 2,339

‌General Medicines turnover - nine months ended 30 September 2026

	Total	US	Europe International	Total	US	Europe International
	£m	£m	£m £m	$m	$m	$m $m
Respiratory	4,981	2,634	1,012 1,335	6,675	3,530	1,356 1,789
Anoro Ellipta	405	137	191 77	543	184	256 103
Flixotide/Flovent	291	197	41 53	390	264	55 71
Relvar/Breo Ellipta	682	228	243 211	914	305	326 283
Seretide/Advair	574	187	121 266	769	251	162 356
Trelegy Ellipta	2,208	1,570	265 373	2,959	2,104	355 500
Ventolin	455	229	80 146	610	307	107 196
Other Respiratory	366	86	71 209	490	115	95 280
Other General Medicines	2,043	128	479 1,436	2,738	172	642 1,924
Blujepa	2	2	- -	3	3	- -
Other General Medicines	2,041	126	479 1,436	2,735	169	642 1,924
General Medicines	7,024	2,762	1,491 2,771	9,412	3,701	1,998 3,713

Commercial Operations turnover - nine months ended 30 September 2026

Commercial operations turnover	Total	US	Europe International	Total	US	Europe International
	£m	£m	£m £m	$m	$m	$m $m
	24,925	12,976	6,053 5,896	33,400	17,389	8,111 7,900

‌Balance sheet

	30 September 2026 £m	30 September 2026 $m
ASSETS
Non-current assets
Property, plant and equipment	9,431	12,543
Right of use assets	691	919
Goodwill	8,216	10,927
Other intangible assets	25,172	33,479
Investments in associates and joint ventures	49	65
Other investments	814	1,083
Deferred tax assets	6,735	8,958
Derivative financial instruments	54	72
Other non-current assets	2,642	3,514
Total non-current assets	53,804	71,560
Current assets
Inventories	6,300	8,379
Current tax recoverable	302	402
Trade and other receivables	8,223	10,937
Derivative financial instruments	103	137
Liquid investments	28	37
Cash and cash equivalents	2,934	3,902
Assets held for sale	5	7
Total current assets	17,895	23,801
TOTAL ASSETS	71,699	95,361
LIABILITIES
Current liabilities
Short-term borrowings	(2,001) (2,661)
Contingent consideration liabilities	(1,318) (1,753)
Trade and other payables	(15,633) (20,792)
Derivative financial instruments	(164) (218)
Current tax payable	(678) (902)
Short-term provisions	(926) (1,232)
Total current liabilities	(20,720) (27,558)
Non-current liabilities
Long-term borrowings	(21,700) (28,861)
Deferred tax liabilities	(1,670) (2,221)
Pensions and other post-employment benefits	(1,552) (2,064)
Derivative financial instruments	(101) (134)
Other provisions	(751) (999)
Contingent consideration liabilities	(5,311) (7,064)
Other non-current liabilities	(1,532) (2,038)
Total non-current liabilities	(32,617) (43,381)
TOTAL LIABILITIES	(53,337) (70,939)
NET ASSETS	18,362	24,422
EQUITY
Share capital	1,349	1,794
Share premium account	3,507	4,664
Retained earnings	12,458	16,570
Other reserves	1,440	1,915
Shareholders' equity	18,754 24,943
Non-controlling interests	(392) (521)
TOTAL EQUITY	18,362	24,422

US dollar amounts shown in the balance sheet above are calculated using closing rate at 30 September 2026

Q3 2026 US dollar translation

Summary by 6ix AI

Key details

Earlier from GSK